Amphastar Pharmaceuticals (NASDAQ: AMPH) revenue
Amphastar Pharmaceuticals reported revenue of $719.9m for fiscal 2025, 1.7% less than in fiscal 2024 ($732.0m). Since fiscal 2016 its revenue has grown by 182.1%, an average growth of 12.2% a year.
Amphastar Pharmaceuticals's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2017, −5.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $719.9m | −1.7% | $140.4m | 19.5% |
| 2024 | $732.0m | +13.6% | $205.4m | 28.1% |
| 2023 | $644.4m | +29.1% | $197.0m | 30.6% |
| 2022 | $499.0m | +14.0% | $107.5m | 21.5% |
| 2021 | $437.8m | +25.1% | $69.9m | 16.0% |
| 2020 | $349.8m | +8.5% | $11.0m | 3.1% |
| 2019 | $322.4m | +9.4% | −$0.0m | −0.0% |
| 2018 | $294.7m | +22.7% | −$8.6m | −2.9% |
| 2017 | $240.2m | −5.9% | −$1.3m | −0.5% |
| 2016 | $255.2m | — | $15.4m | 6.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Amphastar Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Amphastar Pharmaceuticals ranks 176th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Amphastar Pharmaceuticals, −1.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 174th | NeoGenomics | $727.3m | 10.1% |
| 175th | Pacira Biosciences | $726.4m | 3.6% |
| 176th | Amphastar Pharmaceuticals | $719.9m | −1.7% |
| 177th | Kiniksa Pharmaceuticals International | $677.6m | 60.1% |
| 178th | Ultragenyx Pharmaceutical | $673.0m | 20.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Amphastar Pharmaceuticals
- How much revenue did Amphastar Pharmaceuticals make in fiscal 2025?
- Amphastar Pharmaceuticals reported revenue of $719.9m for fiscal 2025, compared with $732.0m in fiscal 2024.
- How much has the revenue of Amphastar Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $255.2m to $719.9m: 182.1% more, an average growth of 12.2% a year.
- What was the best year for revenue at Amphastar Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2024, with $732.0m.
- Where does Amphastar Pharmaceuticals rank in its sector by revenue?
- It ranks 176th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Amphastar Pharmaceuticals come from?
- From the annual report (Form 10-K) that Amphastar Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Amphastar Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Amphastar Pharmaceuticals: the Amphastar Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.